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CObjectives: Hemodynamic control can improve the outcome of sur-
gery. Esophageal Doppler monitoring measures blood flow by ultra-
sound waves. This work investigates the cost-effectiveness of this pro-
cedure during colorectal resection. Methods: Meta-analyses of
andomized controlled trials of esophageal Dopplermonitoring used in
olorectal resection were conducted to help determine its cost-effec-
iveness. An analytical decision model was used to compare the cost-
ffectiveness of strategies involving conventional clinical assessment
ith or without the measurement of central venous pressure, with or
ithout esophageal Doppler monitoring. Avoided mortality and
voided major complications were used as measures of clinical
ffectiveness. Results: In the meta-analyses comparing conventional
linical assessment plus central venous pressure monitoring with or
ithout esophageal Doppler monitoring, statistically significant differ- O
n de
al So
doi:10.1016/j.jval.2011.02.1176nces in total and major complications favoring the use of Doppler
ere found. No differences were seen in mortality. The use of esopha-
eal Doppler monitoring was associated with lower costs, mainly due
o fewer complications, shorter hospital stays and shorter surgery
imes. Conclusions: Although the information regarding the clinical
ffectiveness of esophageal Doppler monitoring in colorectal resection
s limited, strategies including this form of blood flowmonitoring may
e cost-effective. Further comparisons of Doppler monitoring against
ther hemodynamic monitoring systems should be undertaken.
eywords: cardiac imaging techniques, colorectal surgery, cost-effec-
iveness, Doppler ultrasonography.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The optimization of cardiac output and hemodynamic function
has long been considered a key element for improving the care of
critically ill and high risk surgery patients. Optimal cardiac output
after surgery is associatedwith better tissue perfusion, resulting in
less tissue ischemia, less injury following reperfusion, lower infec-
tion rates, better healing, and reduced cardiac strain [1].
Intraoperative hypoperfusion of the gut has been identified in
ver 60% of patients undergoing major surgery, a problem associ-
ted with increased morbidity and a longer hospital stay [2]. The
onsensus is that tissue hypoperfusion and the activation of sys-
emic inflammation should be avoided [3]. Esophageal Doppler
onitoring (EDM) provides an instantaneous representation of
eat-to-beat hemodynamic function; it therefore allows for the
apid correction of hypovolemia and oxygen debt [4]. Accurate
uidance provided by EDM regarding the need for intraoperative
uid could therefore reduce the risk of tissue injury.[3].
A number ofminimally invasive hemodynamicmonitoring op-
ions, including EDM, have been developed to avoid the need for
ulmonary arterial catheterization (PAC). The latter technique has
een gradually abandoned in many countries owing to the lack of
vidence of it providing any benefit to patients, the risks its use
* Address correspondence to: Sergio Maeso, Unidad de Evaluació
Madrid, 28013 Spain.
E-mail: smaemar@hotmail.com.
1098-3015/$36.00 – see front matter Copyright © 2011, Internation
Published by Elsevier Inc.entails, and its associated costs [5,6]. Esophageal Dopplermonitor-
ing measures blood flow velocity in the descending thoracic aorta
using a flexible ultrasonic probe inserted via the mouth or nose
into the patient’s esophagus. Briefly, the measurement of the
blood flow velocity combined with an estimation of the cross-sec-
tional area of the aorta (derived fromanomogramaccording to the
age, height and weight of the patient, or by direct calculation via
ultrasonographic imaging) allows continuous monitoring of the
cardiac output and hemodynamic status. In addition, if values
such as the central venous pressure (CVP) and blood pressure are
known, other variables such as the systemic vascular resistance
can be estimated. The training required to perform EDM isminimal
and the technique has a good safety profile. The probe, however, is
generally not well tolerated by conscious patients and its use is typ-
ically restricted to patients under sedation or anesthesia – which is
usually thecase insurgeryandcritical care. Furtherdetailson theuse
and contraindications of EDM are described in detail elsewhere [7,8].
Other alternatives to PAC include transesophageal echocardiogra-
phy (TEE), systems based on the analysis of the pulse wave, and
dilution methods. However, owing to the lack of data, these ap-
proaches are not considered in the present work.
The conventional clinical assessment (CCA) of surgical pa-
tients involves the non-invasive assessment of numerous vari-
Tecnologías Sanitarias, Agencia Laín Entralgo C/ Gran Vía, 27,
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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819V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 1 8 – 8 2 6ables, including hemodynamic variables such as the heart rate,
the systolic blood pressure, and the urine volume. According to
hospital policy and clinician preferences, CCAmay include the use
of a central venous catheter for the measurement of CVP.
Summary of the available evidence regarding the clinical
effectiveness of EDM
Several systematic reviews have been published on the clinical
effectiveness of EDM [9,10], which has been studied in 10 random-
ized controlled trials (RCTs) [3,4,11–18]. Two of these refer to its use
in high dependency units (HDU) [11,14] while eight involve surgi-
al settings [3,4,12,13,15–18] (one cardiac surgery study [15], one
tudy on several types of major surgery[13], two on femoral frac-
ure repair [16,17], and four on colorectal resection [CR] surgery
3,4,12,18]).
The latter four RCTswere examined as part of a recent system-
tic review [9]. Three were included in the Agency for Healthcare
esearch and Quality (AHRQ) review [10] and were considered to
e of high quality based on a 25-question survey. These four RCTs
ompared different strategies and reported different intermediate
i.e., duration of surgery, fluid therapy administered, length of hos-
ital stay, admission to anHDU) andfinal (i.e., complications,mor-
ality) outcome measures (Table 1).
The small size of these RCTs does not allow robust conclusions to
e drawn regarding mortality rates. Since these studies provide the
est available evidence, however, the mortality rates recorded were
ncluded in the analyses performed in the present work. In each of
he three studies comparing CCA plus themeasurement of CVP plus
DM(CCACVPEDM) toCCACVP [3,4,18] onepatientdied in the
ontrol group. In the study byDodd [12] therewere three deaths, one
n the CCA EDM group, and two in the CCA group.
The most common complications recorded were pneumonia,
Table 1 – Summary of available evidence from randomized
monitoring during elective colorectal resection surgery.
Conway, 20024
Patients (n) 55 (29 vs. 28) 1
Comparisons CCA  CVP  EDM
vs. CCA  CVP
C
Mortality
Number of deaths 0; 1
P value NI
HDU stay due to major
complication
Major complications (n) 0; 5
P value 0.020
Median (range) 0; 3 (1–5)
Total complications
Number of complications 5; 9
P value NI
Hospital stay
Median (IQR) 12 (7–103); 11 (7–30)* 1
P value NI
Fluid administration
Crystalloids (ml, median) NI
P value NI
Colloids (ml, median) 28; 19.4†
P value 0.020
Total (ml, median) 64.6; 55.2†
P value  0.050
CCA, conventional clinical assessment; CVP, central venous pressure
interquartile range; NI, not indicated.
* Total range; † ml/kg.urgical site infection, wound dehiscence and arrhythmias. Con- say [4] and Noblett [3] reported that no patient in their CCA 
VP  EDM groups required critical care, whereas 18% (n  5) and
2% (n  6) required critical care in the CCA  CVP arm of each
tudy. Dodd [12] reported, however, that 35% (n 7) of their CCA
DM and 25% (n  5) of their CCA patients required critical care.
hree of the four RCTs [3,4,18] examined had fewer total compli-
ations in the  EDM group; two reported these differences to be
ignificant [3,18]. In addition, two of the four RCTs [3,18] reported a
tatistically significant shorter hospital stay for patients in their
DM groups. Thus, the use of EDM seems to reduce the complica-
ion rate and the hospital stay.
To our knowledge, no full economic assessments of this device
n different surgical settings have been conducted; all such evalu-
tions should take into account a specific medical setting [19].
The present study assessed, from the Spanish public health
ystem perspective, the cost-effectiveness of the optimization of
emodynamic function guided by EDM compared with CCA in pa-
ients undergoing CR, based on short-term surgical outcomes.
Methods
Synthesis of evidence regarding clinical effectiveness
Three of the RCTs [3,4,18] reported in the collected systematic
eviews [9,10] compared CCA  CVP  EDM to CCA  CVP in CR.
eta-analyses for mortality, major complications, and total com-
licationswere conducted.Mantel-Hansel fixed effectmethod risk
atios (RR)were calculated. BecauseWakeling [18] reported noma-
or complications, this study was not included in the present
eta-analysis for this variable [20]. A fixed effectmethodwas used
or the meta-analyses of the above risk ratios because it was as-
trolled trials on the use of esophageal Doppler
akeling,
200518
Noblett, 20063 Dodd, 200712
4 vs. 64) 103 (51 vs. 52) 40 (20 vs. 20)
CVP  EDM
CCA  CVP
CCA  CVP  EDM
vs. CCA  CVP
CCA  EDM
vs.CCA
0; 1 0; 1 1; 2
NI 0.990 NI
NI 0; 6 7; 5
NI NI NI
NI NI 3 (2–10); 2 (5–10)
24; 38 13; 22 NI
0.050 0.043 NI
5); 11.5 (4.75) 7 (3–35); 9 (4–45) 8 (5–34); 9 (5–27)
0.031 0.005  0.050
000; 3000 2298; 2,625 2875; 2325
 0.050 0.077 NI
000; 1500 1340; 1209 1355; 1000
 0.010 0.397 NI
00; 4,500 3638; 3,864 4230; 3,325
NI NI NI
, esophageal Doppler monitoring; HDU, high dependence unit; IQR,con
W
28 (6
CA 
vs.
0 (5.7
3
2
50
; EDMumed therewas neither clinical nor statistical heterogeneity (I2
i820 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 1 8 – 8 2 650%). Review Manager version 5.0 software (RevMan, The Co-
chrane Collaboration, The Nordic Cochrane Centre, Copenhagen,
Denmark) was used for all calculations.
General characteristics of the economic model used to assess
cost-effectiveness
Conventional clinical assessment involved the monitoring of car-
diac output via the measurement of clinical variables such as the
heart rate, blood pressure and urine volume. Central venous pres-
sure was measured via a central venous catheter, finally EDM in-
volved cardiac output monitoring with an esophageal ultrasound
system and the calculation of blood flow through the descending
aortic artery.
An analytical decisionmodelwith four strategies (CCACVP
EDM versus CCA  CVP versus CCA  EDM versus CCA) was con-
structed (Fig. 1) to compare the cost-effectiveness of hemody-
namic function optimization. These strategies were chosen be-
cause they are some of the most commonly used in clinical
settings and RCTs.
The decision model considered costs and outcomes until hos-
pital discharge; it was assumed that cardiac output control sys-
tems and fluid administration during surgery would not influence
outcomes following discharge. This assumption was also made in
all the RCTs. Long-term results were estimated as part of a sensi-
tivity analysis.
Avoidedmortality, or avoided complications plus avoidedmor-
Fig. 1 – Economic decision model tree for hemodynamic fun
monitoring. CCA, conventional clinical assessment; CVP, cetality, was used as alternative clinical effectiveness measures.Clinical effectiveness data
Estimates for the effectiveness of the CCA  CVP strategy were
obtained from the combined information in the studies reporting
data on the risk of death (three studies, N 144) [3,4,18] and those
reporting onmajor complications (two studies, N 80) [3,4]. These
values were used for the base-case analysis. Probability data for
the CCA  CVP  EDM arm were calculated as the product of the
probabilities for CCA  CVP and the relative risk associated with
the corresponding alternatives. Finally, for the CCA alone strategy,
data were obtained from Dodd [12]. In the absence of data for the
RRs for CCA versus CCA  EDM, data from other high-risk surger-
es were used (Table 2) [16,17]. The probability data for CCA EDM
were estimated using the same methods as described for CCA 
CVP  EDM.
The length of time spent in critical care was based on the data
of Conway (Table 2) [4]. The total hospital stay for each group was
obtained from Wakeling [18], who reported a statistically signifi-
cant difference in hospital stay (1.1 days fewer) for patients who
underwent EDM. It was assumed that patients who underwent
CCACVPhad the same length of hospital stay as thosewhowere
subjected to CCA alone. The duration of surgery was calculated as
the weighted average of data presented by Noblett [3] and Conway
[4] (Table 2).
Cost data
The cost of the EDM probes (provided by themanufacturers; Table
2) was deemed to include the cost of the disposable probe and the
monitoring with intraoperative esophageal Doppler
venous pressure; EDM, esophageal Doppler monitoring.ction
ntralrequired monitoring equipment. Equipment costs for each usage
821V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 1 8 – 8 2 6of the system were calculated. The calculations assumed that the
equipment would last 5 years and would be used 125 times per
year; other utilization rates were tested in sensitivity analyses.
Table 2 – Data used in base case and sensitivity analyses.
Base case
Source Value
Relative risks*
CCA  CVP vs. CCA  CVP
 EDM (1)
Mortality Conway4, Noblett3,
Wakeling18
0.33
Major complications Conway4, Noblett3 0.10
CCA vs. CCA  EDM (2)
Mortality Venn17, Sinclair16 0.98
Major complications Venn17 0.48
Probabilities
CCA  CVP (3)
Mortality Conway4, Noblett3,
Wakeling18
0.021
Major complications Conway4, Noblett3 0.113
CCA  CVP  EDM
Mortality (1)* (3) 0.007
Major complications (1)* (3) 0.011
CCA (4)
Mortality Dodd12 0.100
Major complications Dodd12 0.150
CCA  EDM
Mortality (2)* (4) 0.098
Major complications (2)* (4) 0.048
Base case
Source Value Units
Surgery time
CCA  CVP  EDM Noblett3, Conway4 142.8 Min
CCA  CVP Noblett3, Conway4 158.3 Min
CCA  EDM Noblett3, Conway4 142.8 Min
CCA Noblett3, Conway4 158.3 Min
Hospital stay
CCA  CVP  EDM Wakeling18 12.0 Days
CCA  CVP Wakeling18 13.1 Days
CCA  EDM Wakeling18 12.0 Days
CCA Wakeling18 13.1 Days
HDU stay
CCA  CVP  EDM Conway4 3.0 Days
CCA  CVP Conway4 3.0 Days
CCA  EDM Conway4 3.0 Days
CCA Dodd12 2.0 Days
Cost
Operating theater Finance department 16.47 E/
min
Hospital stay Finance department 493 E/day
HDU stay Finance department 1,417 E/day
EDM Provider 201.25 E
CVP HULP 44.25 E
CCA, conventional clinical assessment; CVP, central venous pressure
unit; min, minute; RR, relative risk; SD, standard deviation; HULP, La
* Deterministic analysis includes 95% CI for relative risk.Capital costs of the EDM were converted to an equivalent annualcost [21,22] applying a 3% [23,24] inflation increase to adjust for
consecutive years of usage.
Central venous catheter costs were provided by the anesthesi-
rministic
sitivity
nalysis
Probabilistic sensitivity analysis
Max. Distrib. Mean Min. Max. SD
2.07 Lognormal 0.526 0.014 11.757 0.627
0.76 Lognormal 0.186 0.002 4.973 0.283
3.72 Lognormal 1.248 0.073 12.929 0.944
0.88 Lognormal 0.517 0.113 2.228 0.204
— Beta 0.021 0.001 0.096 0.012
— Beta 0.112 0.008 0.242 0.031
— — 0.010 0.000 0.308 0.015
— — 0.020 0.000 0.407 0.028
— Beta 0.098 0.001 0.356 0.058
— Beta 0.146 0.004 0.512 0.067
— — 0.089 0.000 0.661 0.081
— — 0.059 0.001 0.377 0.040
rministic
sitivity
alysis
Probabilistic sensitivity analysis
. Max. Distrib. Mean Min. Max. SD
158.3 Gamma 145 26 382 45
— Gamma 156 20 492 57
158.3 Gamma 145 26 382 45
— Gamma 156 20 492 57
13.1 Gamma 12.03 0.58 52.31 6.05
— Gamma 13.04 0.79 52.82 6.57
13.1 Gamma 12.03 0.58 52.31 6.05
— Gamma 13.04 0.79 52.82 6.57
— Gamma 2.99 0.14 11.77 1.49
— Gamma 3.08 0.12 12.60 1.52
— Gamma 2.99 0.14 11.77 1.49
3.0 Gamma 2.00 0.06 7.90 1.01
5 — Gamma 16.50 0.68 59.60 8.24
— Gamma 491.42 22.49 1,901.14 244.36
— Gamma 1,405.20 101.55 5191.02 701.73
8 299.91 Gamma 200.48 12.55 805.20 101.08
76.50 Gamma 44.61 1.36 198.28 22.57
uros; EDM, esophageal Doppler monitoring, HDU; high-dependence
niversity Hospital.Dete
sen
a
Min.
0.05
0.01
0.26
0.12
—
—
—
—
0.05
0.10
—
—
Dete
sen
an
Min
—
—
—
—
—
—
—
—
—
—
—
—
5.7
296
855
188.8
12
; E, E
Paz Uology service of the La Paz University Hospital, which confirmed
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822 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 1 8 – 8 2 6the institution’s equal use of two kinds of catheter costing €12
Euros and €76.5 Euros, respectively (many types of differently
priced catheters are in fact available) (Table 2).
Operating theater time was considered as a cost input. Thus,
staff time associated with inserting the probe and taking the EDM
readings was included within the total surgery time.
Resource use data (surgery time, hospital stay and HDU stay)
were obtained frompublished sources [3,4,12,18]. The unit costs of
surgical theater use, hospital stay, and HDU stay were obtained
from the Salud Madrid accounting system (Consejería de Salud de
la Comunidad de Madrid, 2007) (Table 2).
Costs were adjusted to 2007 prices, when appropriate, using
the Spanish consumer price index. The costs associated with pa-
tients who died were considered equivalent to those for patients
with complications because the RCTs examined recorded HDU
stays for patients who eventually died [3,4].
Cost-effectiveness analysis
The costs used in the present analysis are presented in 2007
Euros. Avoided mortality and avoided complications plus
avoided mortality were used as alternative effectiveness mea-
sures. The discounting of future costs and benefits was not re-
quired because the time horizon of the analysis was V1 year
(indeed, only until hospital discharge) [21]. Those strategies of
lower effectiveness and higher cost were considered as domi-
nated; incremental cost-effectiveness ratios (ICERs) were not
calculated in these cases.
Sensitivity analysis
One way deterministic sensitivity analyses were performed to
understand the individual impact of the uncertain values for
some variables, and a probabilistic analysis performed to study
the joint impact of all variables expressed as probability distri-
butions.
The cost variablesweremodified using published values (Table
2) [25,26]. The distributions were selected following Briggs [27,28],
epending on the variable type (e.g., beta distribution for proba-
ilities, lognormal for RR, and gamma for time and cost variables).
he probabilistic analysis involved aMonte-Carlo simulation with
0,000 iterations. The results of this analysis are presented as cost-
ffectiveness acceptability curves. Central to the assessment of
ost-effectiveness is the value that society would place on gaining
n additional unit of effectiveness. Therefore, by knowing a par-
icular “willingness to pay” value on the horizontal axis, the prob-
bility of its being cost-effective can be obtained from the vertical
xis.
The net monetary benefit of each alternative to conventional
ssessment was determined [27]. As part of the sensitivity analy-
is, the costs generated by patients and the quality of the rest of
heir lives following CR were estimated. It was assumed that pa-
ients discharged alive would generate the same costs and have
he same quality-adjusted life year (QALY) gained, as described by
e Verteuil et al. [29]. The costs of the latter study were converted
nto Euros using purchasing power parity values for Spain (http://
ww.who.int/choice/costs/ppp/en/ [Accessed 26 October 2010]).
Results
Synthesis of results on clinical effectiveness
In the meta-analyses comparing CCA  CVP  EDM versus CCA 
CVP, statistically significant differences were found in the total
number of complications (RR  0.61; 95% CI, 0.45–0.82) and major
omplications (RR  0.08; 95% CI, 0.01–0.62), favoring the  EDM
lternative (1.6 and 12.5 times lower, respectively). No significant
ifference was seen between the groups in terms of mortality(RR  0.33; 95% CI, 0.05–2.07). Figure 2 shows the results of the
meta-analysis.
Cost-effectiveness analysis
CCACVP EDMdominated over all the other alternatives, being
ssociated with lower mortality and fewer complications as well
s lower costs (Table 3). The survival rate was 99% whereas the
roportion of individualswho suffered nomajor complicationwas
8%. Themean cost per patientwas €8579. TheCCACVP strategy
as associated with a survival rate of 98%, the proportion of indi-
iduals with no major complications was 87%, and the mean cost
er patient was €9490. The RRs for mortality and major complica-
ions for the CCA CVP EDM strategy comparedwith the CCA
VP strategy were 0.33 (95% CI, 0.05–2.07) and 0.08 (95% CI, 0.01–
.62) respectively. In addition, for the CCA  CVP  EDM strategy
compared with the CCA  CVP strategy), the number needed to
reat (NNT) associated with an avoided major complication was 9
atients, and the NNT associated with an avoided death was 72
atients (statistical significance not reached). The associated fi-
ancial saving associated with CCA  CVP  EDM over the CCA 
VP strategy was calculated at €911 per patient treated.
Sensitivity analysis
Sensitivity analysis was used to examine the cost-effectiveness re-
sults recorded. In one-way sensitivity analysis, the results were only
sensitive to the relative risk of mortality. Because the difference be-
tween the overall mortality results for the CCA  CVP  EDM and
CCACVPstrategiesdidnot reach statistical significance, theCCA
VP EDM strategy does not appear to always be the best option.
When mortality was regarded as being the same for the two
strategies (RR of mortality equal 1) and the RR for major complica-
tions was taken as the top value of the confidence interval (0.76),
the CCACVP EDM strategy allowed a saving of €667 per patient
compared to the CCA  CVP strategy.
The results were also sensitive to differences in the assumed
length of hospital stay because this is amajor determinant of cost.
When there was no difference in hospital stay between the CCA
CVP  EDM and the CCA  CVP strategies, the cost of the EDM-
ased alternative increased to €9121 Euros and the saving per pa-
ient decreased to €369.
Figure 3 reveals that CCA and CCA  EDM are unlikely to be
cost-effective unless willingness to pay is close to zero. Of the
remaining alternatives, CCA  CVP  EDM is more likely than
CA CVP to be cost-effective over a wide range of willingness to
ay, but the difference in probabilities is modest at 0.2 to 0.25. The
robability of CCA  CVP  EDM being cost-effective ranges from
.4 rising to no more than 0.6 at €50,000 per death avoided, the
reatest willingness to pay value that was considered.
Figure 4 shows the net monetary benefit of CCA CVP  EDM,
CCA CVP and CCA EDM over CCA for a willingness to pay for a
death avoided of between €0 and €50,000. The CCA  CVP  EDM
alternative is associated with the greatest mean net monetary
benefit whatever the willingness to pay is. However, it should be
noted that these results also reveal the 50% CCA  CVP  EDM
credibility intervals overlap with the mean values of the other
alternatives.
Table 4 shows that, in the long-term strategies, and consider-
ing QALYs and care costs, EDM dominates non-EDM strategies.
The incremental cost-effectiveness ratio of CCACVP EDMover
CCA  EDM is €118.65 per QALY.
Discussion
In the present analyses, based on the results of four studies with a
total of 343 patients, and comparing all possible monitoring com-
binations, statistically significant differences were found in terms
823V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 1 8 – 8 2 6of total and major complications that favored the use of the Dop-
pler-based alternatives. No significant differences were seen in
terms of mortality.
A cost-effectiveness analysis of the use of EDM in CR was also
undertaken, including the best evidence available in the literature.
To our knowledge, this is the first full economic evaluation of EDM.
The CCA CVP EDM strategy wasmore effective and less costly
Fig. 2 – Meta-analyses comparing CCA + CVP + EDM and CCA
and total complications ± mortality. CCA, conventional clini
Doppler monitoring; M-H, Mantel-Haenszel.
Table 3 – Results of the economic decision model analysis.
Strategies Survival
rate
Free of major
complication rate
CCA 0.900 0.750
CCA  EDM 0.902 0.830
CCA  CVP 0.979 0.867
CCA  CVP  EDM 0.993 0.982
Costs are in Euros.
CCA, conventional clinical assessment; CVP, central venous pressure
ness ratio.than any of the other strategies. Cost savings were mainly due to
fewer complications, shorter hospital stays, and shorter interven-
tion times.
The present analysis only considered costs and clinical effec-
tiveness until hospital discharge. Because themost common com-
plications included pneumonia, surgical site infection, or dehis-
cence and arrhythmias, it was assumed that no differences would
VP in CR with respect to mortality, major complications,
ssessment; CVP, central venous pressure; EDM, esophageal
Cost
(€)
ICER mortality
avoided
ICER complication
avoided
9540.94 Dominated Dominated
8955.34 Dominated Dominated
9490.33 Dominated Dominated
8579.21 — —
, esophageal Doppler monitoring; ICER, incremental cost-effective-+ C
cal a; EDM
824 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 1 8 – 8 2 6be appreciated in terms of post-discharge long-term outcomes.
The hospital perspective is a good proxy for an overall health care
system perspective — the complications described in RCTs, such
as pneumonia, surgical site complications or arrhythmias are
dealt with during the hospital stay and require no primary care
visits following discharge.
Fig. 3 – Acceptability curves showing the likelihood of each
pay for a death avoided (in Euros). CCA, conventional clinica
Doppler monitoring.
Fig. 4 – Net monetary benefits of each strategy comparing w
willingness to pay for a death avoided (in Euros). CCA, conv
EDM, esophageal Doppler monitoring.The robustness of the present analysis is at its greatest for the
comparison between CCA  CVP  EDM and CCA  CVP because
there have been more trials involving these alternatives; this al-
lowed standard meta-analysis methods to be used. The Mantel-
Hansel method was chosen since it is recommended for testing
differences in proportions when events are relatively uncommon
egy being cost-effective at different levels of willingness to
essment; CVP, central venous pressure; EDM, esophageal
onventional clinical assessment at different levels of
nal clinical assessment; CVP, central venous pressure;strat
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825V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 1 8 – 8 2 6[20]. The comparisons made between alternatives not containing
CVP measurements were indirect and must be understood with
caution. For the CCAalone strategy, datawere obtained fromDodd
[12] (the only source available for such information). Moreover,
hose published data regarding the comparison of CCA  EDM
ersus CCA did not involve colorectal surgery. Therefore, RRswere
alculated using data from other RCTs [16,17] involving high-risk
urgery. Some of the RCTs included pooled patient data with and
ithout CVPmeasurements. Consequently, amodelwith only two
lternatives, CCA EDM (with orwithout CVP) versus CCA (with or
ithout CVP) could be used to determine the cost-effectiveness of
dding EDM to CR treatment. The results of Dodd included in this
ork were obtained as a personal communication of unpublished
bservations. This study was included because it is an RCT, and
hus allowed two more alternatives to be considered in the cost-
ffectiveness analysis. The results taken from this study, however,
ere not used in the core comparison i.e., CCA  CVP  EDM
versus CCA  CVP.
Due to the nature of the EDM procedure, RCTs on EDM are
unlikely to be blinded. These studies are subject to the classic bias
of non-blinded studies. In addition, clinicians might be more
aware of the information provided by the new device and, there-
fore, more likely to make a decision on its further use quickly. If
this were the case, the effect of EDM might be overestimated and
one would have to wait until the device were used more generally
for this source of bias to disappear.
As explained in the Methods section, unit cost data were ob-
tained from theMadrid Health System, the La Paz Hospital finance
department, and from device manufacturers; it was assumed that
such data would best reflect real practice. Even so, this informa-
tion was compared with published cost data [25,26]; no significant
differences were seen in the results.
It was assumed that the costs for patients who died were the
same as those for patients who had complications because the
RCTs also indicated previous HDU stays for such patients before
their deaths [3,4]. This might, however, have resulted in an over-
estimation of the costs. Several diagnostic-related group costing
studies have reported that, in general, patients who die in the
hospital actually incur lower costs than those who survive due to
their relatively short stays and restricted use of other resources.
Although the present study sought to use themost robust data
available, the literature used to populate the present economic
decision model may not represent actual practice. Further re-
search for this patient group, i.e., those undergoing CR, should
include the use of different clinical protocols detailing the intra-
and postoperative volume of fluid needed to improve patient out-
comes [30]. The limited evidence available meant that it was not
possible to include surgicalmonitoringwith strategies using other
minimally invasive monitoring systems (e.g., thermo-dilution or
lithium dilution) in the present analysis.
The focus of the present studywas the cost-effectiveness of the
intraoperative monitoring of hemodynamic function by EDM.
Other researchers have considered the use of hemodynamicmon-
Table 4 – Results on utilities of the economic decision mod
Strategies Costs (€)  Costs (
CCA 14,830
CCA  EDM 14,256
CCA  CVP 15,244
CCA  CVP  EDM 14,415 159
Costs are in Euros.
, incremental change; CCA, conventional clinical assessment; CV
incremental cost-effectiveness ratio; QALY, quality-adjusted life yeaitoring in the postoperative period in an HDU setting [14,31]. Thepresent study did not consider this setting; further researchwould
be required to evaluate this.
Kehlet [32] proposed a series of measures designed to improve
ecovery following major colorectal surgery within the well-
nown fast-track or enhanced recovery program. Themost recent
rotocols of this kind include EDMduring colorectal surgery. Other
easures proposed were optimized nutrition, early mobilization,
voiding colon preparation, and avoiding drainages.
A theoretical reduction in mortality would induce higher costs
erived from the health care of surviving patients, but would also
ncrease global survival and the QALYs obtained. In the present
tudy, it was assumed that the long-term costs generated, and the
ALYs gained, were the same for all discharged patients [29].
hese assumptions may not always hold because the type and
eriousness of complications are different, and some may have a
ore serious impact on patient’s later well-being. No information,
owever, was available in this regard. Further work would be
eeded to address this possibility. It is unlikely, however, that
ufficient complications of sufficient seriousness to alter the over-
ll understanding of the present results would occur. Further-
ore, the present results suggest that if EDM were always used,
ewer such complications would occur.
Conclusions
In conclusion, if the results of the small size RCTs examined in the
present study are confirmed in daily practice, the present assess-
ment indicates that a strategy of hemodynamic monitoring that
includes CCA  CVP  EDM during elective colorectal surgery
ould be cost-effective, improving health outcomes and saving
ealth care resources.
Further primary studies comparing other forms of monitoring,
uch as pulse wave analysis monitoring, are required. These stud-
es should include economic assessments so that different strate-
ies can be compared. Well designed studies are needed to con-
rm whether the estimated savings and improved outcomes
btained with EDM hold true in practice. Similar studies should
lso be performed in patients undergoing other types of surgery.
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